Andrew Bayliffe

Andrew Bayliffe is the Chief Scientific Officer at Marengo Therapeutics, where Andrew has been since January 2020. Prior to this role, Andrew worked as a Venture Partner at Apple Tree Partners starting in October 2019. With an extensive background in research and development, Andrew held various leadership positions at GSK from June 2000 to January 2020, including Head of Respiratory and Inflammation Research Unit and Global Development Leader for Respiratory & Inflammation. Before joining GSK, Andrew worked as a Research Scientist at AstraZeneca. Andrew earned their PhD in Pharmacology and Molecular Biology from the University of Leeds and their BS in Pharmacology from The Manchester Metropolitan University.